| Rajdeep Kaur Kahlon, | |
|
6420 Rio Linda Blvd, Rio Linda, CA 95673-3332 | |
| (916) 992-5403 | |
| Not Available |
| Full Name | Rajdeep Kaur Kahlon |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 6420 Rio Linda Blvd, Rio Linda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891334652 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 81520 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rajdeep Kaur Kahlon, 5545 Marconi Ave Apt 211, Carmichael, CA 95608-4449 Ph: (510) 552-4866 | Rajdeep Kaur Kahlon, 6420 Rio Linda Blvd, Rio Linda, CA 95673-3332 Ph: (916) 992-5403 |
News Archive
A new study led by scientists at The Scripps Research Institute could help researchers develop personalized treatments for alcoholism and alcohol use disorder.
The first mobile safety laboratory to operate under Biosafety Level 3 has been in use in South Africa since May 2011. As development of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, this special truck is used for testing and advising patients with AIDS and tuberculosis. The mobile laboratory can save patients' lives in remote areas because it cuts the waiting time between diagnosis and the start of treatment to just one day.
Investigators who studied a group of recreational marathon runners have established that strenuous exercise such as running a marathon can damage the heart muscle. Although they found the effect is temporary and reversible, they warn that these effects are more widespread in less fit distance runners and that recreational distance runners should prepare properly before marathons.
A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.
Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth.
› Verified 1 days ago
Tram Ngoc Bui, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6420 Rio Linda Blvd, Rio Linda, CA 95673 Phone: 916-992-5403 |